Increased CXCR4 Use of HIV-1 Subtype C Identified by Population Sequencing in Patients Failing Antiretroviral Treatment Compared with Treatment-Naive Patients in Botswana
Restricted accessResearch articleFirst published online May, 2014
Increased CXCR4 Use of HIV-1 Subtype C Identified by Population Sequencing in Patients Failing Antiretroviral Treatment Compared with Treatment-Naive Patients in Botswana
HIV-1 uses the coreceptors CCR5 and/or CXCR4 for cell entry. Monotropic CCR5-using variants are found early in the infection while CXCR4-using variants may appear after progression to AIDS. CXCR4 use may consist of both monotropic and dualtropic viruses. The viral phenotype is important in evaluating the response to CCR5 inhibitors, a new class of antiviral drugs. The coreceptor use of HIV-1 was investigated using population sequencing in 24 patients from Botswana, carrying HIV-1 subtype C and failing antiretroviral treatment, while 26 treatment-naive patients acted as controls. Single genome sequencing was used to discern minor HIV-1 populations in the treatment-experienced group. The Geno2Pheno method was employed to predict the coreceptor use phenotype from HIV-1 env gp120 V3 DNA sequences. The glycan-charge model adjusted for subtype C was also used for phenotype prediction. The viral phenotype of population sequences was predicted using Geno2Pheno in 24/24 treatment-experienced patients, of whom eight (33%) were predicted to harbor CXCR4-using strains as compared to 2/26 in the treatment-naive group (p=0.03). Single genome sequencing generated 4–23 clones/patient in the treatment-experienced group. Altogether, 90/295 (31%) putative CXCR4-using clones were identified. In 10/24 (42%) treated patients at least one clone was predicted to be CXCR4-using, further increasing the amount of identified treatment-experienced patients with CXCR4 use. Although subtype C is usually associated with comparatively little CXCR4 use, the frequency of CXCR4 use in treatment-experienced patients with subtype C can be higher, which may have implications for the administration of CCR5 inhibitors in this patient group.
Get full access to this article
View all access options for this article.
References
1.
AlkhatibG, CombadiereC, BroderCC, et al.: CC CKR5: A RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science, 1996; 272(5270):1955–1958.
2.
DengH, LiuR, EllmeierW, et al.: Identification of a major co-receptor for primary isolates of HIV-1. Nature, 1996; 381(6584):661–666.
3.
DragicT, LitwinV, AllawayGP, et al.: HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature, 1996; 381(6584):667–673.
4.
FengY, BroderCC, KennedyPE, and BergerEA: HIV-1 entry cofactor: Functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science, 1996; 272(5263):872–877.
5.
BersonJF, LongD, DoranzBJ, RuckerJ, JirikFR, and DomsRW: A seven-transmembrane domain receptor involved in fusion and entry of T-cell-tropic human immunodeficiency virus type 1 strains. J Virol, 1996; 70(9):6288–6295.
6.
BergerEA, DomsRW, FenyoEM, et al.: A new classification for HIV-1. Nature, 1998; 391(6664):240.
7.
ConnorRI, SheridanKE, CeradiniD, ChoeS, and LandauNR: Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. J Exp Med, 1997; 185(4):621–628.
8.
ScarlattiG, TresoldiE, BjorndalA, et al.: In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression. Nat Med, 1997; 3(11):1259–1265.
9.
CasperC, NaverL, ClevestigP, et al.: Coreceptor change appears after immune deficiency is established in children infected with different HIV-1 subtypes. AIDS Res Hum Retroviruses, 2002; 18(5):343–352.
10.
KootM, van LeeuwenR, de GoedeRE, et al.: Conversion rate towards a syncytium-inducing (SI) phenotype during different stages of human immunodeficiency virus type 1 infection and prognostic value of SI phenotype for survival after AIDS diagnosis. J Infect Dis, 1999; 179(1):254–258.
11.
ShepherdJC, JacobsonLP, QiaoW, et al.: Emergence and persistence of CXCR4-tropic HIV-1 in a population of men from the multicenter AIDS cohort study. J Infect Dis, 2008; 198(8):1104–1112.
12.
HuangW, EshlemanSH, TomaJ, et al.: Coreceptor tropism in human immunodeficiency virus type 1 subtype D: High prevalence of CXCR4 tropism and heterogeneous composition of viral populations. J Virol, 2007; 81(15):7885–7893.
13.
KaleebuP, NankyaIL, YirrellDL, et al.: Relation between chemokine receptor use, disease stage, and HIV-1 subtypes A and D: Results from a rural Ugandan cohort. J Acquir Immune Defic Syndr, 2007; 45(1):28–33.
14.
WambuiV, KiptooM, KinyuaJ, et al.: Predicted HIV-1 coreceptor usage among Kenya patients shows a high tendency for subtype D to be CXCR4 tropic. AIDS Res Ther, 2012; 9(1):22.
15.
YuXF, WangZ, BeyrerC, et al.: Phenotypic and genotypic characteristics of human immunodeficiency virus type 1 from patients with AIDS in northern Thailand. J Virol, 1995; 69(8):4649–4655.
16.
UtaipatU, DuerrA, RudolphDL, et al.: Coreceptor utilization of HIV type 1 subtype E viral isolates from Thai men with HIV type 1-infected and uninfected wives. AIDS Res Hum Retroviruses, 2002; 18(1):1–11.
17.
ToSW, ChenJH, WongKH, ChanKC, ChenZ, and YamWC: Determination of the high prevalence of dual/mixed- or X4-tropism among HIV type 1 CRF01_AE in Hong Kong by genotyping and phenotyping methods. AIDS Res Hum Retroviruses, 2013; 29(8):1123–1128.
18.
HemelaarJ, GouwsE, GhysPD, and OsmanovS: Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS, 2006; 20(16):W13–W23.
19.
TscherningC, AlaeusA, FredrikssonR, et al.: Differences in chemokine coreceptor usage between genetic subtypes of HIV-1. Virology, 1998; 241(2):181–188.
20.
AbebeA, DemissieD, GoudsmitJ, et al.: HIV-1 subtype C syncytium- and non-syncytium-inducing phenotypes and coreceptor usage among Ethiopian patients with AIDS. AIDS, 1999; 13(11):1305–1311.
21.
BjorndalA, SonnerborgA, TscherningC, AlbertJ, and FenyoEM: Phenotypic characteristics of human immunodeficiency virus type 1 subtype C isolates of Ethiopian AIDS patients. AIDS Res Hum Retroviruses, 1999; 15(7):647–653.
22.
PingLH, NelsonJA, HoffmanIF, et al.: Characterization of V3 sequence heterogeneity in subtype C human immunodeficiency virus type 1 isolates from Malawi: Underrepresentation of X4 variants. J Virol, 1999; 73(8):6271–6281.
23.
CoetzerM, NedellecR, CilliersT, MeyersT, MorrisL, and MosierDE: Extreme genetic divergence is required for coreceptor switching in HIV-1 subtype C. J Acquir Immune Defic Syndr, 2011; 56(1):9–15.
24.
JohnstonER, ZijenahLS, MutetwaS, KantorR, KittinunvorakoonC, and KatzensteinDA: High frequency of syncytium-inducing and CXCR4-tropic viruses among human immunodeficiency virus type 1 subtype C-infected patients receiving antiretroviral treatment. J Virol, 2003; 77(13):7682–7688.
25.
ConnellBJ, MichlerK, CapovillaA, VenterWD, StevensWS, and PapathanasopoulosMA: Emergence of X4 usage among HIV-1 subtype C: Evidence for an evolving epidemic in South Africa. AIDS, 2008; 22(7):896–899.
26.
SinghA, SunpathH, GreenTN, et al.: Drug resistance and viral tropism in HIV-1 subtype C-infected patients in KwaZulu-Natal, South Africa: Implications for future treatment options. J Acquir Immune Defic Syndr, 2011; 58(3):233–240.
27.
GreenTN, ArcharyM, GordonML, et al.: Drug resistance and coreceptor usage in HIV type 1 subtype C-infected children initiating or failing highly active antiretroviral therapy in South Africa. AIDS Res Hum Retroviruses, 2012; 28(4):324–332.
28.
SchuitemakerH, van 't WoutAB, and LussoP: Clinical significance of HIV-1 coreceptor usage. J Transl Med, 2011; 9(Suppl 1):S5.
29.
FDA approves maraviroc tablets. AIDS Patient Care STDS, 2007; 21(9):702.
30.
WilkinTJ, SuZ, KuritzkesDR, et al.: HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. Clin Infect Dis, 2007; 44(4):591–595.
31.
ParczewskiM, Leszczyszyn-PynkaM, UrbanskaA, BanderD, and Boron-KaczmarskaA: Genotypic tropism of antiretroviral-treated patients with drug resistant HIV-1. J Med Virol, 2011; 83(11):1869–1875.
32.
HuntPW, HarriganPR, HuangW, et al.: Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia. J Infect Dis, 2006; 194(7):926–930.
33.
WagnerTA and FrenkelLM: Potential limitation of CCR5 antagonists: Drug resistance more often linked to CXCR4-utilizing than to CCR5-utilizing HIV-1. AIDS, 2008; 22(17):2393–2395.
34.
MaedaK, DasD, NakataH, and MitsuyaH: CCR5 inhibitors: Emergence, success, and challenges. Expert Opin Emerg Drugs, 2012; 17(2):135–145.
BussmannH, WesterCW, NdwapiN, et al.: Five-year outcomes of initial patients treated in Botswana's National Antiretroviral Treatment Program. AIDS, 2008; 22(17):2303–2311.
37.
UNAIDS, NACA: Progress Report of the National Response to the 2001 Declaration of Commitment on HIV and AIDS. Botswana Country Report 2010. Reporting Period: 2008–2009. UNAIDS; 2010. http://data.unaids.org/pub/Report/2010/botswana_2010_country_progress_report_en.pdf.
38.
Doualla-BellF, GaseitsiweS, NdunguT, et al.: Mutations and polymorphisms associated with antiretroviral drugs in HIV-1C-infected African patients. Antivir Chem Chemother, 2004; 15(4):189–200.
39.
Ndung'uT, SepakoE, McLaneMF, et al.: HIV-1 subtype C in vitro growth and coreceptor utilization. Virology, 2006; 347(2):247–260.
40.
LeitnerT, KorovinaG, MarquinaS, SmolskayaT, and AlbertJ: Molecular epidemiology and MT-2 cell tropism of Russian HIV type 1 variant. AIDS Res Hum Retroviruses, 1996; 12(17):1595–1603.
41.
ClevestigP, MaljkovicI, CasperC, et al.: The X4 phenotype of HIV type 1 evolves from R5 in two children of mothers, carrying X4, and is not linked to transmission. AIDS Res Hum Retroviruses, 2005; 21(5):371–378.
42.
LengauerT, SanderO, SierraS, ThielenA, and KaiserR: Bioinformatics prediction of HIV coreceptor usage. Nat Biotechnol, 2007; 25(12):1407–1410.
43.
ClevestigP, PramanikL, LeitnerT, and EhrnstA: CCR5 use by human immunodeficiency virus type 1 is associated closely with the gp120 V3 loop N-linked glycosylation site. J Gen Virol, 2006; 87(Pt 3):607–612.
44.
PramanikL, FriedU, ClevestigP, and EhrnstA: Charged amino acid patterns of coreceptor use in the major subtypes of human immunodeficiency virus type 1. J Gen Virol, 2011; 92(Pt 8):1917–1922.
45.
VandekerckhoveLPR, WensingAMJ, KaiserR, et al.: European guidelines on the clinical management of HIV-1 tropism testing. Lancet Infect Dis, 2011; 11(5):394–407.
46.
LinNH, SmeatonLM, GiguelF, et al.: Prevalence and clinical associations of CXCR4-using HIV-1 among treatment-naive subtype C-infected women in Botswana. J Acquir Immune Defic Syndr, 2011; 57(1):46–50.
47.
KayeS, ComberE, Tenant-FlowersM, and LovedayC: The appearance of drug resistance-associated point mutations in HIV type 1 plasma RNA precedes their appearance in proviral DNA. AIDS Res Hum Retroviruses, 1995; 11(10):1221–1225.
48.
SeclenE, GarridoC, Gonzalez MdelM, et al.: High sensitivity of specific genotypic tools for detection of X4 variants in antiretroviral-experienced patients suitable to be treated with CCR5 antagonists. J Antimicrob Chemother, 2010; 65(7):1486–1492.
49.
VerhofstedeC, BrudneyD, ReynaertsJ, et al.: Concordance between HIV-1 genotypic coreceptor tropism predictions based on plasma RNA and proviral DNA. HIV Med, 2011; 12(9):544–552.
50.
VerhofstedeC, VandekerckhoveL, EygenVV, et al.: CXCR4-using HIV type 1 variants are more commonly found in peripheral blood mononuclear cell DNA than in plasma RNA. J Acquir Immune Defic Syndr, 2009; 50(2):126–136.
51.
ObermeierM, SymonsJ, and WensingAM: HIV population genotypic tropism testing and its clinical significance. Curr Opin HIV AIDS, 2012; 7(5):470–477.
52.
JohnsonJA, LiJF, MorrisL, et al.: Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated. J Infect Dis, 2005; 192(1):16–23.
53.
JordanMR, KearneyM, PalmerS, et al.: Comparison of standard PCR/cloning to single genome sequencing for analysis of HIV-1 populations. J Virol Methods, 2010; 168(1-2):114–120.
54.
O'MearaD, WilbeK, LeitnerT, HejdemanB, AlbertJ, and LundebergJ: Monitoring resistance to human immunodeficiency virus type 1 protease inhibitors by pyrosequencing. J Clin Microbiol, 2001; 39(2):464–473.
55.
ArcherJ, BravermanMS, TaillonBE, et al.: Detection of low-frequency pretherapy chemokine (CXC motif) receptor 4 (CXCR4)-using HIV-1 with ultra-deep pyrosequencing. AIDS, 2009; 23(10):1209–1218.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
